OADR-ORWH Funding Information and Funding Opportunities

OADR-ORWH in Fiscal Year 2023

The funding strategy for the inaugural year of OADR-ORWH funding was based on recommendations from NIH institutes and centers (ICs), and diseases included in the autoimmune portfolio in the NASEM report. In FY23, OADR-ORWH supported a total of 41 awards across 12 individual ICs. This included 15 extramural co-funding awards, 3 R56 bridge funding awards, 2 Accelerating Medicines Partnership® Autoimmune and Immune-Mediated Diseases (AMP® AIM) awards, 10 intramural co-funding awards, 5 intramural scientific fellowships, and 6 EXposome in Autoimmune Disease Collaborating Teams PLANning Awards (EXACT-PLAN). The EXACT-PLAN Notice of Special Interest (NOSI) (NOT-OD-23-112) was developed by OADR-ORWH in partnership with the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), the National Institute of Environmental Health Sciences (NIEHS), and NIH Institute, Center, and Office (ICO) partners. The EXACT-PLAN focuses on supporting the design, development, and implementation of a future national, interdisciplinary, collaborative, team science research network that will advance the study of the exposome in autoimmune disease. The funded awards spanned basic to translational science, clinical, and public health research focused on autoimmune disease.

See Figures a-c: Office of Autoimmune Disease Research (OADR-ORWH) Fiscal Year (FY) 2023 Funding Allocation by [a] Activity and [b-c] Administering Institute/Center.

Funding Opportunities

StatusTitleAnnouncement NumberDue Dates(s)Expiration Date(s)
ACTIVERequest for Information (RFI): Proposed Use of Common Data Elements (CDEs) for NIH-Funded Clinical Research and TrialsNOT-OD-24-0634/20/20244/20/2024
ACTIVEUnderstanding Chronic Conditions Understudied Among Women (R21 Clinical Trial Optional)RFA-OD-23-0136/20/20246/21/2024
ACTIVEUnderstanding Chronic Conditions Understudied Among Women (R01 Clinical Trial Optional)RFA-OD-23-0146/20/20246/21/2024
ACTIVENotice of Special Interest (NOSI): Research Supplements to Promote Re-Entry, Re-integration into, and Re-training in Health-Related Research Careers (Admin Supp - Clinical Trial Not Allowed)NOT-OD-23-170Vary by NIH Institutes and Centers (ICs)10/09/2026
ACTIVENotice of Special Interest: Women’s Health ResearchNOT-OD-24-079Vary by NIH ICs11/05/2027
CLOSEDNotice of Special Interest (NOSI): EXposome in Autoimmune Disease Collaborating Teams PLANning Awards (EXACT-PLAN) (Clinical Trials Not Allowed) NOT-OD-23-1126/16/20236/17/2023
CLOSEDNotice of Special Interest (NOSI): Research on the Health of Women of Understudied, Underrepresented and Underreported (U3) Populations (Admin Supp Clinical Trial Optional)NOT-OD-24-0321/31/20242/1/2024
CLOSEDRequest for Information (RFI): Inviting Input on an NIH-Wide Strategic Plan for Autoimmune Disease ResearchNOT-OD-24-0493/01/20243/01/2024
CLOSEDTeam Science Leadership Scholars Program (LSP) in Women’s Health, Autoimmune and Immune-Mediated Diseases 2.0RFA-AMPAIM-LSP-23-0024/01/20244/01/2024